{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:07:43Z","timestamp":1789747663661,"version":"4.0.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020948","name":"AstraZeneca Gothenburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.kint.2026.06.043","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T23:17:57Z","timestamp":1785194277000},"page":"977-987","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["New insights from DAPA-CKD indicate that dapagliflozin modulates key pathways related to kidney outcomes"],"prefix":"10.1016","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4083-0087","authenticated-orcid":false,"given":"Mark Andr\u00e9","family":"de la Rambelje","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Jongs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Greasley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus","family":"Agren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1531-4294","authenticated-orcid":false,"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Hammarstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. David","family":"Sj\u00f6str\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan A.","family":"Voors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-3730","authenticated-orcid":false,"given":"Hiddo J.L.","family":"Heerspink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2026.06.043_bib1","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.06.043_bib2","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.06.043_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/dbi20-0040","article-title":"SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation","volume":"70","author":"Tuttle","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2026.06.043_bib4","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2026.06.043_bib5","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S2213-8587(20)30382-X","article-title":"Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomized, placebo-controlled trial","volume":"9","author":"Jensen","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kint.2026.06.043_bib6","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1111\/dom.14352","article-title":"Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: results from the DEFINE-HF trial","volume":"23","author":"Nassif","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.kint.2026.06.043_bib7","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ekir.2023.11.020","article-title":"Randomized trial of SGLT2 inhibitor identifies target proteins in diabetic kidney disease","volume":"9","author":"Ahluwalia","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.06.043_bib8","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.2337\/dc20-0456","article-title":"Mechanisms of sodium-glucose cotransporter 2 inhibition: insights from large-scale proteomics","volume":"43","author":"Ferrannini","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2026.06.043_bib9","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s00125-021-05512-5","article-title":"Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2, and KIM-1 in the CANVAS trial","volume":"64","author":"Sen","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.kint.2026.06.043_bib10","doi-asserted-by":"crossref","first-page":"6340","DOI":"10.1038\/s41467-023-41642-7","article-title":"Proteomics of CKD progression in the Chronic Renal Insufficiency Cohort","volume":"14","author":"Dubin","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2026.06.043_bib11","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41591-019-0415-5","article-title":"A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes","volume":"25","author":"Niewczas","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2026.06.043_bib12","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1093\/eurheartj\/ehac495","article-title":"Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme","volume":"43","author":"Zannad","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kint.2026.06.043_bib13","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/ndt\/gfaf180","article-title":"Protein profiles and associated biological pathways among different etiologies of chronic kidney disease: new insights from DAPA-CKD","volume":"41","author":"De La Rambelje","year":"2026","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.06.043_bib14","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/ndt\/gfz290","article-title":"Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial","volume":"35","author":"Heerspink","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.06.043_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2021.100168","article-title":"Proximity extension assay in combination with next-generation sequencing for high-throughput proteome-wide analysis","volume":"20","author":"Wik","year":"2021","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.kint.2026.06.043_bib16","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.2337\/dc20-0630","article-title":"Profibrotic circulating proteins and risk of early progressive renal decline in patients with type 2 diabetes with and without albuminuria","volume":"43","author":"Ihara","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2026.06.043_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.615306","article-title":"Integrative informatics analysis of transcriptome and identification of interacted genes in the glomeruli and tubules in CKD","volume":"7","author":"Liu","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.kint.2026.06.043_bib18","first-page":"124","article-title":"HE4\u2014a biomarker and target in renal fibrosis","volume":"9","author":"Allison","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2026.06.043_bib19","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s102380300006","article-title":"High levels of serum soluble CD27 correlated with renal dysfunction","volume":"2","author":"Nakatsuji","year":"2003","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.kint.2026.06.043_bib20","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.3390\/ijms23063284","article-title":"The signaling pathway of TNF receptors: linking animal models of renal disease to human CKD","volume":"23","author":"Lousa","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.kint.2026.06.043_bib21","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12916-023-02891-x","article-title":"The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank","volume":"21","author":"Hydes","year":"2023","journal-title":"BMC Med"},{"key":"10.1016\/j.kint.2026.06.043_bib22","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.biopha.2018.02.090","article-title":"Central role of dysregulation of TGF-\u03b2\/Smad in CKD progression and potential targets of its treatment","volume":"101","author":"Chen","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.kint.2026.06.043_bib23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.krcp.2011.12.005","article-title":"The insulin-like growth factor system in chronic kidney disease: pathophysiology and therapeutic opportunities","volume":"31","author":"Oh","year":"2012","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.kint.2026.06.043_bib24","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2337\/dc25-1722","article-title":"Baseline risk and longitudinal changes in KidneyIntelX.dkd and its association with kidney outcomes in the CANVAS and CREDENCE trials","volume":"49","author":"Moedt","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2026.06.043_bib25","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1046\/j.1523-1755.2002.00433.x","article-title":"Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury","volume":"62","author":"Han","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.06.043_bib26","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1080\/0886022X.2016.1193816","article-title":"Kidney injury molecule-1 in kidney disease","volume":"38","author":"Yin","year":"2016","journal-title":"Ren Fail"},{"key":"10.1016\/j.kint.2026.06.043_bib27","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/jdi.13139","article-title":"Circulating kidney injury molecule-1 as a biomarker of renal parameters in diabetic kidney disease","volume":"11","author":"Gohda","year":"2020","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.kint.2026.06.043_bib29","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1161\/01.RES.0000154262.07264.12","article-title":"Collagen triple helix repeat containing 1, a novel secreted protein in injured and diseased arteries, inhibits collagen expression and promotes cell migration","volume":"96","author":"Pyagay","year":"2005","journal-title":"Circ Res"},{"key":"10.1016\/j.kint.2026.06.043_bib30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12079-021-00625-3","article-title":"CTHRC1 promotes growth, migration and invasion of trophoblasts via reciprocal Wnt\/\u03b2-catenin regulation","volume":"16","author":"Li","year":"2022","journal-title":"J Cell Commun Signal"},{"key":"10.1016\/j.kint.2026.06.043_bib31","doi-asserted-by":"crossref","first-page":"10847","DOI":"10.1002\/jcb.28376","article-title":"Adipose mesenchymal stem cell-derived exosomes promote cell proliferation, migration, and inhibit cell apoptosis via Wnt\/\u03b2-catenin signaling in cutaneous wound healing","volume":"120","author":"Ma","year":"2019","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.kint.2026.06.043_bib32","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1182\/blood.V94.4.1440","article-title":"Proteolytic processing of big endothelin-3 by the Kell blood group protein","volume":"94","author":"Lee","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.kint.2026.06.043_bib33","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/ki.2014.143","article-title":"Endothelin and endothelin antagonists in chronic kidney disease","volume":"86","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.06.043_bib34","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1161\/CIRCULATIONAHA.122.063327","article-title":"Endothelin-1, outcomes in patients with heart failure and reduced ejection fraction, and effects of dapagliflozin: findings from DAPA-HF","volume":"147","author":"Yeoh","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2026.06.043_bib35","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/nature14601","article-title":"Regulation of mitochondrial morphology and function by stearoylation of TFR1","volume":"525","author":"Senyilmaz","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.kint.2026.06.043_bib36","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/ng.3465","article-title":"A missense mutation in TFRC, encoding transferrin receptor 1, causes combined immunodeficiency","volume":"48","author":"Jabara","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.kint.2026.06.043_bib37","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300049","article-title":"Dapagliflozin and anemia in patients with chronic kidney disease","volume":"2","author":"Koshino","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.kint.2026.06.043_bib38","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1002\/hep4.2069","article-title":"Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus","volume":"6","author":"Arai","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.kint.2026.06.043_bib39","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jchf.2021.04.014","article-title":"Mechanistic insights of empagliflozin in nondiabetic patients with HFrEF","volume":"9","author":"Requena-Ib\u00e1\u00f1ez","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.kint.2026.06.043_bib40","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1186\/s12933-024-02481-y","article-title":"Dapagliflozin mitigates cellular stress and inflammation through PI3K\/AKT pathway modulation in cardiomyocytes, aortic endothelial cells, and stem cell-derived \u03b2 cells","volume":"23","author":"Alsereidi","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.kint.2026.06.043_bib41","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/bs.apha.2017.08.002","article-title":"Matrix metalloproteinases, vascular remodeling, and vascular disease","volume":"81","author":"Wang","year":"2018","journal-title":"Adv Pharmacol"},{"key":"10.1016\/j.kint.2026.06.043_bib42","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/kisup.2014.16","article-title":"Wnt\/\u03b2-catenin signaling and kidney fibrosis","volume":"4","author":"Tan","year":"2014","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kint.2026.06.043_bib43","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.kint.2016.08.020","article-title":"IL-4\/IL-13-mediated polarization of renal macrophages\/dendritic cells to an M2a phenotype is essential for recovery from acute kidney injury","volume":"91","author":"Zhang","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.06.043_bib44","doi-asserted-by":"crossref","first-page":"18306","DOI":"10.1074\/jbc.RA119.010348","article-title":"Protein tyrosine phosphatase receptor type R (PTPRR) antagonizes the Wnt signaling pathway in ovarian cancer by dephosphorylating and inactivating \u03b2-catenin","volume":"294","author":"Wang","year":"2019","journal-title":"J Biol Chem"},{"key":"10.1016\/j.kint.2026.06.043_bib45","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/proteomes9030032","article-title":"A novel urinary proteomics classifier for noninvasive evaluation of interstitial fibrosis and tubular atrophy in chronic kidney disease","volume":"9","author":"Catanese","year":"2021","journal-title":"Proteomes"},{"key":"10.1016\/j.kint.2026.06.043_bib46","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/ndt\/gfaa307","article-title":"Urine proteomics for prediction of disease progression in patients with IgA nephropathy","volume":"37","author":"Rudnicki","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.06.043_bib47","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1186\/s12967-025-06977-3","article-title":"In silico prediction of optimal multifactorial intervention in chronic kidney disease","volume":"23","author":"Latosinska","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.kint.2026.06.043_bib48","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0140-6736(23)02230-4","article-title":"Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial","volume":"402","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2026.06.043_bib49","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/dom.70193","article-title":"Proteins and signalling pathways targeted by dapagliflozin and finerenone: insights from DAPA-CKD and FIGARO-DKD","volume":"28","author":"De la Rambelje","year":"2026","journal-title":"Diabetes Obes Metab"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826006149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826006149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:37:43Z","timestamp":1789745863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253826006149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0085253826006149"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2026.06.043","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New insights from DAPA-CKD indicate that dapagliflozin modulates key pathways related to kidney outcomes","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.06.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}